The United States is confronting its highest annual measles caseload in 35 years, a public health challenge that underscores persistent vulnerabilities in vaccination coverage across the nation. In 2026, the country recorded 2,318 confirmed measles infections, a figure not seen since the late 1980s. The demographic breakdown of these cases highlights a particular impact on younger populations, with 69 percent of infections occurring in individuals aged 19 or younger. Children under five years old accounted for one-fifth of all reported cases, a group particularly susceptible to severe complications from the highly contagious viral disease.
A critical factor in the resurgence of measles is the sustained decline in vaccination rates. Data indicates that kindergarten measles, mumps, and rubella (MMR) vaccination coverage currently stands at 92.5 percent. This figure falls below the 95 percent threshold widely recognized by public health experts as necessary to achieve effective herd immunity, a level of community protection that prevents widespread transmission. The vast majority of those affected by measles, 93 percent, were unvaccinated individuals, reinforcing the efficacy of the MMR vaccine in preventing infection. The re-emergence of measles, once considered largely eradicated in the U.S. due to robust vaccination programs, presents a significant public health concern, requiring renewed focus on immunization efforts and public education.
Globally, the Democratic Republic of the Congo (DRC) has reported a substantial Ebola outbreak, with nearly 3,000 confirmed cases identified following a comprehensive data review. This outbreak has resulted in more than 1,269 deaths, highlighting the severe challenges of containing the deadly virus in regions with complex logistical and healthcare infrastructure. The scale of the outbreak underscores the ongoing need for international support and rapid response mechanisms to mitigate the spread of highly infectious diseases in vulnerable populations. Efforts by international health organizations and local authorities continue to focus on surveillance, contact tracing, and safe burial practices to bring the outbreak under control.
Domestically, food safety agencies have expanded investigations into several significant incidents. The Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) are continuing to probe a cyclospora outbreak linked to contaminated shredded iceberg lettuce. The implicated lettuce, imported from central Mexico, has been tied to 1,947 cases of illness and 98 hospitalizations across nine states. Fortunately, no deaths have been reported in connection with this outbreak. In response to the findings, the affected lettuce was promptly recalled from the market, and the processing facility identified as the source was temporarily closed to address sanitation and safety protocols. Cyclospora cayetanensis is a microscopic parasite that can cause intestinal illness, with symptoms including watery diarrhea, loss of appetite, weight loss, cramping, bloating, nausea, and fatigue.
In a separate food safety development, Midwest Poultry Services initiated a recall of nearly 1.6 million dozen eggs due to a potential risk of Salmonella contamination. Salmonella bacteria can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems. Healthy individuals infected with Salmonella often experience fever, diarrhea, nausea, vomiting, and abdominal pain. The large scale of the egg recall underscores the vigilance required in the food production industry to prevent widespread public health hazards.
Legal and regulatory actions within the pharmaceutical sector have also drawn attention. A federal judge in Illinois dismissed a shareholder lawsuit filed against Abbott Laboratories concerning its 2022 powdered infant-formula recall. Judge Steven Seeger ruled that the shareholders had not presented sufficient evidence to demonstrate that the company intended to deceive them regarding the issues at its Sturgis, Michigan, plant. The 2022 recall had significant implications for infant formula supply chains and prompted widespread concern among parents and regulators. The judge’s decision clarifies the legal threshold for proving corporate intent in such shareholder actions.
Further regulatory shifts by the FDA have impacted pharmaceutical compounding and drug access. The agency moved to exclude the peptide emideltide from its pharmacy-compounding lists, a decision that affects how certain medications can be prepared and dispensed by compounding pharmacies. Conversely, the FDA recommended Semax for inclusion on these lists, indicating its potential utility in compounded formulations. These decisions reflect the FDA’s ongoing efforts to regulate the safety and efficacy of compounded drugs, which are custom-prepared medications for individual patients.
In a significant legal development regarding reproductive health, a federal judge in Virginia ordered the FDA to reassess special licensing requirements for prescribing mifepristone. Mifepristone is a medication used in medication abortions and for managing miscarriages. The judge’s order mandates a review of specific restrictions that have governed the drug’s distribution and prescription, potentially impacting access for patients and prescribing physicians. This ruling is part of broader legal challenges to the FDA’s regulatory authority over certain medications and could lead to changes in how mifepristone is made available across the country.
Merck, a major pharmaceutical company, has also made strides in global health by signing agreements covering an experimental HIV pill in 129 countries. These agreements aim to expand access to a promising new treatment for HIV, particularly in low- and middle-income countries where the burden of the disease remains significant. Such initiatives are crucial for advancing global public health goals and ensuring that innovative medical treatments reach populations most in need.
Why it matters in Charleston
The confluence of national and international health developments holds tangible implications for Charleston. The resurgence of measles, driven by declining vaccination rates, poses a direct public health concern for institutions like the Medical University of South Carolina (MUSC) and Roper St. Francis Healthcare, which must remain prepared for potential outbreaks and manage public health messaging. Foodborne illness investigations, such as the cyclospora outbreak and the egg recall, highlight the importance of robust local food safety practices and the need for vigilance in a globalized food supply chain that serves Charleston’s residents and numerous restaurants. Furthermore, national shifts in pharmaceutical regulation and access, including decisions on compounding and mifepristone, directly affect healthcare providers and patients within the Charleston County area, influencing treatment options and prescribing practices. These broader trends underscore the interconnectedness of global and national health with the daily lives and healthcare infrastructure of Charleston.
